Venatorx Pharmaceuticals Announces Positive Results for Phase 3 Clinical Trial (CERTAIN-1) of Cefepime-Taniborbactam for Treatment of cUTI

Cefepime-taniborbactam met the primary noninferiority efficacy endpoint and demonstrated statistical superiority to meropenem

Cefepime-taniborbactam was well-tolerated with similar safety profile to meropenem

NDA on track to be submitted in the fourth quarter 2022

See more here